{
    "id": 27321,
    "fullName": "SLC16A1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SLC16A1 positive indicates the presence of the SLC16A1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6566,
        "geneSymbol": "SLC16A1",
        "terms": [
            "SLC16A1",
            "HHF7",
            "MCT",
            "MCT1",
            "MCT1D"
        ]
    },
    "variant": "positive",
    "createDate": "12/01/2017",
    "updateDate": "12/01/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19069,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY-8002 inhibited proliferation of a SLC16A1-positive diffuse large B-cell lymphoma cell line in culture, however, did not reduce tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 8690,
                "therapyName": "BAY-8002",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19070,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3965 inhibited proliferation of a SLC16A1-positive diffuse large B-cell lymphoma cell line in culture, however, did not significantly inhibit tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 653,
                "therapyName": "AZD3965",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19072,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3965 inhibited proliferation of a SLC16A1-positive colorectal carcinoma cell line in culture, however, did not reduce tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 653,
                "therapyName": "AZD3965",
                "synonyms": null
            },
            "indication": {
                "id": 80199,
                "name": "colorectal carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19068,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3965 inhibited proliferation of SLC16A1-positive burkitt lymphoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 653,
                "therapyName": "AZD3965",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19071,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY-8002 inhibited proliferation of a SLC16A1-positive colorectal carcinoma cell line in culture, however, did not inhibit tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 8690,
                "therapyName": "BAY-8002",
                "synonyms": null
            },
            "indication": {
                "id": 80199,
                "name": "colorectal carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19067,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY-8002 inhibited proliferation of SLC16A1-positive burkitt lymphoma cell lines in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 30115664).",
            "molecularProfile": {
                "id": 28744,
                "profileName": "SLC16A1 positive"
            },
            "therapy": {
                "id": 8690,
                "therapyName": "BAY-8002",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16079,
                    "pubMedId": 30115664,
                    "title": "Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30115664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28744,
            "profileName": "SLC16A1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}